27465797|t|Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose - induced molecular pathways
27465797|a|Considering the referred beneficial effects of protein restriction on diabetic nephropathy (DN) and the role of renal endothelium in its pathogenesis, we evaluated the effect of general control nonderepressible 2 (GCN2) kinase activation, a sensor of amino acid deprivation, on known detrimental molecular pathways in primary human glomerular endothelial cells (GEnC). GEnC were cultured under normal or high -glucose conditions in the presence or not of the GCN2 kinase activator, tryptophanol. Glucose transporter 1 (GLUT1) expression was assessed by western blotting and reactive oxygen species (ROS) using a fluorogenic probe. Activities of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and protein kinase C (PKC) were assessed by commercial activity assays, sorbitol colorimetrically, methylglyoxal by ELISA and O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins by western blotting. High glucose induced GLUT1 expression, increased ROS and inhibited GAPDH. Also it increased the polyol pathway product sorbitol, PKC activity, the level of the O-GlcNAc-modified proteins that produced by the hexosamine pathway and the advanced glycation endproducts' precursor methylglyoxal. Co-treatment of GEnC with tryptophanol restored the above high-glucose - induced alterations. Activation of GCN2 kinase protects GEnC from high-glucose - induced harmful molecular pathways. By inhibiting concurrently many pathways involved in DN pathogenesis, GCN2 kinase may serve as a pharmaceutical target for the treatment of DN.
27465797	0	10	Activation	T044	C0014429
27465797	14	55	general control nonderepressible 2 kinase	T116,T126	C2354171
27465797	56	64	protects	T033	C1545588
27465797	65	70	human	T016	C0086418
27465797	71	99	glomerular endothelial cells	T025	C1182791
27465797	113	125	high-glucose	T033	C0860803
27465797	128	135	induced	T169	C0205263
27465797	136	154	molecular pathways	T044	C1704259
27465797	202	209	protein	T116,T123	C0033684
27465797	210	221	restriction	T169	C0443288
27465797	225	245	diabetic nephropathy	T047	C0011881
27465797	247	249	DN	T047	C0011881
27465797	267	272	renal	T023	C0022646
27465797	273	284	endothelium	T024	C0014257
27465797	292	304	pathogenesis	T046	C0699748
27465797	309	318	evaluated	T058	C0220825
27465797	333	381	general control nonderepressible 2 (GCN2) kinase	T116,T126	C2354171
27465797	382	392	activation	T044	C0014429
27465797	396	402	sensor	T075	C0600364
27465797	406	416	amino acid	T116,T121,T123	C0002520
27465797	417	428	deprivation	T080	C0871712
27465797	451	469	molecular pathways	T044	C1704259
27465797	481	486	human	T016	C0086418
27465797	487	515	glomerular endothelial cells	T025	C1182791
27465797	517	521	GEnC	T025	C1182791
27465797	524	528	GEnC	T025	C1182791
27465797	534	542	cultured	T059	C0430400
27465797	559	563	high	T080	C0205250
27465797	559	583	high -glucose conditions	T047	C0020456
27465797	614	625	GCN2 kinase	T116,T126	C2354171
27465797	626	635	activator	T044	C2247123
27465797	637	649	tryptophanol	T116	C0526839
27465797	651	672	Glucose transporter 1	T116,T123	C0168458
27465797	674	679	GLUT1	T116,T123	C0168458
27465797	681	691	expression	T045	C1171362
27465797	696	704	assessed	T052	C1516048
27465797	708	724	western blotting	T059,T063	C0005863
27465797	729	752	reactive oxygen species	T123,T196	C0162772
27465797	754	757	ROS	T123,T196	C0162772
27465797	767	784	fluorogenic probe	T130	C0016321
27465797	786	796	Activities	T044	C0243102
27465797	800	840	glyceraldehyde 3-phosphate dehydrogenase	T116,T126	C3536868
27465797	842	847	GAPDH	T116,T126	C3536868
27465797	853	869	protein kinase C	T116,T126	C0033634
27465797	871	874	PKC	T116,T126	C0033634
27465797	881	889	assessed	T052	C1516048
27465797	893	919	commercial activity assays	T059	C0005507
27465797	921	929	sorbitol	T109,T121	C0037688
27465797	930	946	colorimetrically	T059	C1531834
27465797	948	961	methylglyoxal	T109,T130	C0034338
27465797	965	970	ELISA	T059	C0014441
27465797	975	1035	O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins	T116,T126	C0671368
27465797	1039	1055	western blotting	T059,T063	C0005863
27465797	1057	1069	High glucose	T033	C0860803
27465797	1070	1077	induced	T169	C0205263
27465797	1078	1083	GLUT1	T116,T123	C0168458
27465797	1084	1094	expression	T045	C1171362
27465797	1096	1105	increased	T081	C0205217
27465797	1106	1109	ROS	T123,T196	C0162772
27465797	1114	1123	inhibited	T080	C0311403
27465797	1124	1129	GAPDH	T116,T126	C3536868
27465797	1139	1148	increased	T081	C0205217
27465797	1153	1159	polyol	T109	C0071629
27465797	1160	1167	pathway	T044	C1704259
27465797	1176	1184	sorbitol	T109,T121	C0037688
27465797	1186	1189	PKC	T116,T126	C0033634
27465797	1190	1198	activity	T044	C0243102
27465797	1217	1243	O-GlcNAc-modified proteins	T116,T126	C0671368
27465797	1265	1275	hexosamine	T109,T123	C0019477
27465797	1276	1283	pathway	T044	C1704259
27465797	1292	1323	advanced glycation endproducts'	T109,T123	C0162574
27465797	1324	1333	precursor	T078	C1709634
27465797	1334	1347	methylglyoxal	T109,T130	C0034338
27465797	1349	1361	Co-treatment	T058	C0814472
27465797	1365	1369	GEnC	T025	C1182791
27465797	1375	1387	tryptophanol	T116	C0526839
27465797	1407	1419	high-glucose	T033	C0860803
27465797	1422	1429	induced	T169	C0205263
27465797	1443	1453	Activation	T044	C0014429
27465797	1457	1468	GCN2 kinase	T116,T126	C2354171
27465797	1478	1482	GEnC	T025	C1182791
27465797	1488	1500	high-glucose	T033	C0860803
27465797	1503	1510	induced	T169	C0205263
27465797	1519	1537	molecular pathways	T044	C1704259
27465797	1553	1565	concurrently	T079	C0205420
27465797	1571	1579	pathways	T044	C1704259
27465797	1592	1594	DN	T047	C0011881
27465797	1595	1607	pathogenesis	T046	C0699748
27465797	1609	1620	GCN2 kinase	T116,T126	C2354171
27465797	1636	1650	pharmaceutical	T091	C0031336
27465797	1651	1657	target	T169	C1521840
27465797	1666	1675	treatment	T061	C0087111
27465797	1679	1681	DN	T047	C0011881